Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price

Key Points

• Wedbush raised its price target on Vor Biopharma from $9 to $15 while keeping a "neutral" rating, but the MarketBeat analyst consensus is a "Moderate Buy" with a much higher average target of $50.67, showing wide analyst disagreement.
• VOR stock traded up to $17.19 (market cap $178.9M) and sits within a 52‑week range of $2.62–$65.80, with heavy institutional ownership (97.29%), signaling active investor interest despite recent volatility.
• Vor's pipeline centers on off‑the‑shelf, genome‑edited hematopoietic stem cell therapies, led by VOR33 for relapsed/refractory AML and high‑risk MDS.

Vor Biopharma (NASDAQ:VOR - Get Free Report) had its price objective increased by research analysts at Wedbush from $9.00 to $15.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a "neutral" rating on the stock. Wedbush's price target would suggest a potential downside of 12.71% from the company's current price.

Other research analysts also recently issued research reports about the company. TD Cowen began coverage on Vor Biopharma in a research note on Wednesday, December 17th. They issued a "buy" rating for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Vor Biopharma in a report on Wednesday, January 21st. Wells Fargo & Company initiated coverage on shares of Vor Biopharma in a research report on Thursday, March 19th. They issued an "overweight" rating and a $30.00 price target for the company. Jefferies Financial Group initiated coverage on shares of Vor Biopharma in a research note on Monday. They set a "buy" rating and a $50.00 price target for the company. Finally, Citigroup started coverage on shares of Vor Biopharma in a report on Friday, January 9th. They set a "buy" rating and a $50.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $50.67.

Vor Biopharma Price Performance

VOR stock traded up $2.49 during midday trading on Tuesday, reaching $17.19. 733,064 shares of the stock were exchanged, compared to its average volume of 925,272. Vor Biopharma has a 52 week low of $2.62 and a 52 week high of $65.80. The company has a fifty day moving average price of $14.19 and a 200 day moving average price of $17.85. The stock has a market capitalization of $178.90 million, a PE ratio of -0.04 and a beta of 1.99.

Institutional Trading of Vor Biopharma

Several institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new position in Vor Biopharma during the 4th quarter worth approximately $229,000. Susquehanna Portfolio Strategies LLC bought a new stake in shares of Vor Biopharma in the 4th quarter valued at $134,000. Tudor Investment Corp ET AL bought a new stake in shares of Vor Biopharma in the 4th quarter valued at $2,193,000. Sphera Funds Management LTD. acquired a new stake in shares of Vor Biopharma during the fourth quarter worth $5,368,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of Vor Biopharma during the fourth quarter worth $350,000. 97.29% of the stock is currently owned by institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.